Skip to main content
SpringerLink
Log in

Quetiapine extended release: a guide to its use as adjunctive treatment in major depressive disorder

  • Clinical Questions & Answers on Drugs
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Once-daily oral quetiapine extended release (XR) is effective as an adjunct to antidepressant therapy in the treatment of patients with a major depressive episode and an inadequate response to an antidepressant alone. The tolerability profile of quetiapine XR when administered as adjunctive therapy in patients with major depressive disorder is consistent with that seen in other indications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. World Health Organization. The global burden of disease: 2004 update. Geneva: WHO Press, 2008

    Google Scholar 

  2. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003 Jun 18; 289(23): 3095–105

    Article  PubMed  Google Scholar 

  3. Janicak PG, Dowd SM. Treatment-resistant depression: an update on diagnosis and management. Psychopharm Rev 2009; 44(6): 41–8

    Google Scholar 

  4. Mann JJ. The medical management of depression. N Engl J Med 2005; 353(17): 1819–34

    Article  PubMed  CAS  Google Scholar 

  5. Davidson JRT. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry 2010; 71Suppl. E1: e04

    PubMed  Google Scholar 

  6. Sanford M. Quetiapine extended release: adjunctive treatment in major depressive disorder. CNS Drugs 2011: 25(9): 803–13

    Article  PubMed  CAS  Google Scholar 

  7. Questions and answers on Seroquel XR and associated names (50, 150, 200, 300 and 400 mg prolonged-release tablets containing quetiapine): outcome of a procedure under Article 6(13) of Regulation (EC) 1084/ 2003 as amended. London: European Medicines Agency, 2010 Nov 19

  8. Seroquel XL (quetiapine extended release) 50 mg, 150 mg, 200 mg, 300 mg, 400 mg prolonged-release tablets: summary of product characteristics. Luton: AstraZeneca UK Limited, 2011 Nov 16

  9. Seroquel XR (quetiapine fumarate) tablets: US prescribing information. Wilmington (DE): AstraZeneca, 2011 Dec

  10. Seroquel SR prolonged release tablets: summary of product characteristics [in Portuguese]. Barcarena: AstraZeneca Pharmaceuticals, Ltd, 2011 Nov 16

  11. McIntyre RS, Soczynska JK, Woldeyohannes HO, et al. A preclinical and clinical rationale for quetiapine in mood syndromes. Expert Opin Pharmacother 2007 Jun; 8(9): 1211–9

    Article  PubMed  CAS  Google Scholar 

  12. Nyberg S, Widzowski D. Translational pharmacology of quetiapine and norquetiapine: preclinical findings support multifunctional psychotropic properties [abstract no. PW01-27]. Eur Psychiatry 2010; 25Suppl. 1: 1446

    Article  Google Scholar 

  13. Jensen NH, Rodriguiz RM, Caron MG, et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine’s antidepressant activity. Neuropsychopharmacol 2008 Sep; 33(10): 2303–12

    Article  CAS  Google Scholar 

  14. Bakken GV, Rudberg I, Molden E, et al. Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients. Ther Drug Monit 2011 Apr; 33(2): 222–6

    PubMed  CAS  Google Scholar 

  15. Seroquel Prolong tablets: summary of product characteristics [in Spanish]. Madrid: AstraZeneca Farmacéutica Spain, S.A., 2011 Oct

  16. Bauer M, Pretorius HW, Constant EL, et al. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 2009 Apr; 70(4): 540–9

    Article  PubMed  CAS  Google Scholar 

  17. El-Khalili N, Joyce M, Atkinson S, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2010; 13(7): 917–32

    Article  PubMed  CAS  Google Scholar 

  18. Bauer M, El-Khalili N, Datto C, et al. A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorder. J Affect Disord 2010 Dec; 127(1–3): 19–30

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, Auckland, 0754, New Zealand

    Gillian M. Keating & Mark Sanford

Authors
  1. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark Sanford
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gillian M. Keating.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Keating, G.M., Sanford, M. Quetiapine extended release: a guide to its use as adjunctive treatment in major depressive disorder. Drugs Ther Perspect 28, 7–11 (2012). https://doi.org/10.2165/11209210-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11209210-000000000-00000

Keywords

Search

Navigation